Download PDF
Semin Thromb Hemost 2003; 29(2): 205-212
DOI: 10.1055/s-2003-38836
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Acquired Thrombophilia in Pregnancy: Essential Thrombocythemia

Martin Griesshammer1 , Martin Grünewald2 , Jan J. Michiels3
  • 1Head, Research Laboratory on Hemostasis, Department of Internal Medicine III, Division of Hemostaseology, University of Ulm, Ulm, Germany
  • 2Department of Internal Medicine III, Division of Hemostaseology, University of Ulm, Ulm, Germany
  • 3Director, Goodheart Institute, European Working Group on MPD, Goodheart Institute and Foundation, Rotterdam, The Netherlands
Further Information

Publication History

Publication Date:
23 April 2003 (online)

    Permissions and Reprints

ABSTRACT

The management of pregnant patients with essential thrombocythemia (ET) is a difficult problem. The clinical course of ET is mainly determined by thromboembolic complications. Pregnancy itself is a physiological hypercoagulable state. When ET affects women during pregnancy, an adverse outcome caused by thrombotic complications is a matter of concern. We reviewed 155 pregnancies in 86 women with ET. The success rate (baby alive) was 59%. First-trimester abortion was the most frequent complication and occurred in 31% of pregnancies. Placental infarction caused by thrombosis seemed to be the most consistent pathologic event. Maternal thrombotic or hemorrhagic complications were rare but were more common than those seen in normal pregnancy. Pregnancy itself does not appear to affect adversely the natural course and prognosis of ET. A meta-analysis revealed a significant benefit for aspirin in comparison to no treatment. If cytoreductive therapy becomes necessary, interferon α appears to be the drug of choice. The value of heparin prophylaxis has not been established but may have a role in selected cases.

KEYWORDS

Essential thrombocythemia - pregnancy - treatment - outcome

REFERENCES

  • 1 Pearson T C. Primary thrombocythaemia: diagnosis and management.  Br J Haematol . 1991;  78 145-148
    PubMedGoogle Scholar
  • 2 Genderen van J J P, Michiels J J. Primary thrombocythemia: diagnosis, clinical manifestations and management.  Ann Hematol . 1993;  67 57-62
    CrossrefPubMedGoogle Scholar
  • 3 Thiele J, Kvasnicka H M, Diehl V, Fischer R, Michiels J J. Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies.  Leuk Lymphoma . 1999;  33 207-218
    PubMedGoogle Scholar
  • 4 Rozman C, Giralt M, Feliu E, Rubio D, Cortes M T. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders.  Cancer . 1991;  67 2658-2663
    PubMedGoogle Scholar
  • 5 Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia.  Semin Hematol . 1999;  36 9-13
    PubMedGoogle Scholar
  • 6 Tefferi A, Solberg L A, Silverstein M N. A clinical update in polycythemia vera and essential thrombocythemia.  Am J Med . 2000;  109 141-149
    CrossrefPubMedGoogle Scholar
  • 7 Ruggeri M, Finazzi G, Tosetto A. et al . No treatment for low-risk thrombocythaemia: results from a prospective study.  Br J Haematol . 1998;  103 772-777
    CrossrefPubMedGoogle Scholar
  • 8 Griesshammer M, Bergmann L, Pearson T C. Fertility, pregnancy and the management of myeloproliferative disorders.  Baillieres Clin Haematol . 1998;  11 859-874
    PubMedGoogle Scholar
  • 9 Tefferi A, Fonseca R, Pereira D L, Hoagland H C. A long-term retrospective study of young women with essential thrombocythemia.  Mayo Clin Proc . 2001;  76 22-28
    PubMedGoogle Scholar
  • 10 Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial.  Br J Haematol . 2000;  110 577-583
    CrossrefPubMedGoogle Scholar
  • 11 Griesshammer M, Heimpel H, Pearson T C. Essential thrombocythemia and pregnancy.  Leuk Lymphoma . 1996;  22 57-63
    PubMedGoogle Scholar
  • 12 Wright C A, Tefferi A. A single institutional experience with 43 pregnancies in essential thrombocythemia.  Eur J Haematol . 2001;  66 152-159
    CrossrefPubMedGoogle Scholar
  • 13 Greer I A. Thrombosis in pregnancy: maternal and fetal issues.  Lancet . 1999;  353 1258-1265
    CrossrefPubMedGoogle Scholar
  • 14 Macklon N S, Greer I A. Venous thromboembolic disease in obstetrics and gynaecology: the Scottish experience.  Scot Med J . 1996;  41 83-86
    PubMedGoogle Scholar
  • 15 Bates S M, Ginsberg J S. Thrombosis in pregnancy.  Curr Op Hematol . 1997;  4 335-343
    PubMedGoogle Scholar
  • 16 Cortelazzo S, Viero P, Finazzi G. et al . Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia.  J Clin Oncol . 1990;  8 556-562
    PubMedGoogle Scholar
  • 17 van Genderen J J P, Budde U, Michiels J J, van Strik R, van Vliet H D M H. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count.  Br J Haematol . 1996;  93 962-965
    CrossrefPubMedGoogle Scholar
  • 18 Hoagland H, Silverstein M. Primary thrombocythemia in the young patient.  Mayo Clin Proc . 1978;  53 578-580
    PubMedGoogle Scholar
  • 19 Bellucci S, Janvier M, Tobelem G. et al . Essential thrombocythemias: clinical evolutionary and biological data.  Cancer . 1986;  58 2440-2447
    PubMedGoogle Scholar
  • 20 Beard J, Hillmen P, Anderson C C, Lewis S M, Pearson T C. Primary thrombocythaemia in pregnancy.  Br J Haematol . 1991;  77 371-374
    PubMedGoogle Scholar
  • 21 Leone G, De Stefano V, D'Addosio A. Essential thrombocythemia: pregnancy.  Haematologica . 1991;  76(Suppl 3) 365-367
    PubMedGoogle Scholar
  • 22 Beressi A H, Tefferi A, Silverstein M N, Petitt R M, Hoagland H C. Outcome analysis of 34 pregnancies in women with essential thrombocythemia.  Arch Intern Med . 1995;  155 1217-1222
    CrossrefPubMedGoogle Scholar
  • 23 Pagliaro P, Arrigoni L, Muggiasca M L. et al . Primary thrombocythemia and pregnancy: treatment and outcome in fifteen cases.  Am J Hematol . 1996;  53 6-10
    CrossrefPubMedGoogle Scholar
  • 24 Randi M L, Rossi C, Fabris F, Girolami A. Essential thrombocythemia in young adults: treatment and outcome of 16 pregnancies.  J Intern Med . 1999;  246 517-518
    CrossrefPubMedGoogle Scholar
  • 25 Bangerter M, Guthner C, Beneke H. et al . Pregnancy in essential thrombocythaemia: treatment and outcome of 17 pregnancies.  Eur J Haematol . 2000;  65 165-169
    CrossrefPubMedGoogle Scholar
  • 26 Schmidt-Matthiesen H. Gynäkologie und Geburtshilfe, 8th ed.  Stuttgart: Schattauer Verlag 1992
    Google Scholar
  • 27 Zahner J, Wehmeier A, Schneider W. Pregnancy in essential thrombocythemia. Manifestation time and risk for mother and child.  Dtsch Med Wochenschr . 1995;  120 1517-1523
    PubMedGoogle Scholar
  • 28 Falconer J, Pineo G, Blahey W. et al . Essential thrombocythemia associated with recurrent abortions and fetal growth retardation.  Am J Hematol . 1987;  25 345-347
    CrossrefPubMedGoogle Scholar
  • 29 Willoughby S JB, Fairhead S, Woodcock B E, Pearson T C. Postpartum thrombosis in primary thrombocythaemia.  Eur J Haematol . 1997;  59 121-123
    PubMedGoogle Scholar
  • 30 Sejeny S A, Eastham R D, Baker S R. Platelet counts during normal pregnancy.  J Clin Pathol . 1975;  28 812-813
    CrossrefPubMedGoogle Scholar
  • 31 Turhan A G, Humphries R K, Cashman J D. et al . Transient suppression of clonal hemopoiesis associated with pregnancy in a patient with a myeloproliferative disorder.  J Clin Invest . 1988;  81 1999-2003
    PubMedGoogle Scholar
  • 32 Griesshammer M, Bangerter M, van Vliet H D M H, Michiels J J. Aspirin in essential thrombocythemia: status quo and quo vadis.  Semin Thromb Hemost . 1997;  23 371-377
    PubMedGoogle Scholar
  • 33 Beaufils M, Uzan S, Donsimoni R, Colau J. Prevention of pre-eclampsia by early anti-platelet therapy.  Lancet . 1985;  840-842
    PubMedGoogle Scholar
  • 34 Lowenwirt I, Dadic P, Krishnamurthy V. Essential thrombocythemia and epidural analgesia in the parturient. Does thromboelastography help?.  Reg Anesth . 1996;  21 525-528
    PubMedGoogle Scholar
  • 35 Rai R S, Cohen H, Dave M, Regan L. Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies).  Br Med J . 1997;  314 253-257
    CrossrefPubMedGoogle Scholar
  • 36 Doll D C, Ringenberg Q S, Yarbo J W. Antineoplastic agents and pregnancy.  Semin Oncol . 1989;  16 337-346
    PubMedGoogle Scholar
  • 37 Chaube S, Simmel E, Lacon C. Hydroxyurea, a teratogenic chemical.  Proc Am Assoc Cancer Res . 1963;  4 10
    PubMedGoogle Scholar
  • 38 Diav-Citrin O, Hunnisett L, Sher G D, Koren G. Hydroxyurea use during pregnancy: a case report in sickle cell disease and review of the literature.  Am J Hematol . 1999;  60 148-150
    CrossrefPubMedGoogle Scholar
  • 39 Beard M EJ, Conder J L, Clark V A. Ovarian failure following cytotoxic therapy.  N Z Med J . 1984;  97 759-762
    PubMedGoogle Scholar
  • 40 Goldfinger D, Thompson R, Lowe C, Kurz L, Belkin G. Long-term plateletpheresis in the management of primary thrombocytosis.  Transfusion . 1979;  19 336-338
    CrossrefPubMedGoogle Scholar
      >